Nasdaq GlobeNewswire

Imperial Capital Continues Global Expansion Efforts with the Hiring of Two Senior Structured Products Professionals

Del

LOS ANGELES, June 29, 2017 (GLOBE NEWSWIRE) -- Imperial Capital Group, LLC ("Imperial Capital"), and its affiliate, Imperial Capital (International) LLP ("Imperial UK"), announced today the addition of Itish Popat and Jason Kim to its Structured Products Group. Mr. Popat and Mr. Kim will report to Keith Grimaldi, Managing Director and Head of Structured Products Sales and Trading.

"We are pleased to welcome Itish and Jason to Imperial further complementing our existing Structured Products Group team," said Tom Corcoran, President of Imperial Capital, LLC. "Their deep understanding of structured products and robust industry experience will enable our firm to better serve the US and European institutional investor community as well as adapt to the ever evolving market."

Itish Popat joins Imperial UK as a Managing Director in the Structured Products Sales Group in London and brings more than 20 years of varietal capital markets experience. Most recently, Mr. Popat was a Partner and Head of ABS / Financials Agency Broking Business at Vantage Capital Markets LLP. Prior to Vantage Capital Markets, Mr. Popat was an Executive Director of Fixed Income Sales with UBS and Head of UK / Ireland ABS Sales, where he covered UK & Irish Banks, asset managers, SIV's, insurance companies, pension funds and hedge funds. Prior to joining UBS, Mr. Popat spent just under nine years with HSBC in Fixed Income Sales and Trading. Mr. Popat earned a BA(Hons) in Business Studies from the University of Portsmouth.

Jason Kim joins Imperial Capital, LLC as a Senior Vice President in the Structured Products Trading Group in New York and has over 15 years of experience trading a variety of fixed income products. Most recently, Mr. Kim was an Executive Director at Oppenheimer & Co. Inc. and primarily traded non-agency RMBS as well as CMBS, CLO and ABS bonds.  Prior to Oppenheimer, he held similar roles at JVB Financial, UBS and Deutsche Bank.  Mr. Kim earned a BA in Economics from Northwestern University and an MBA in Finance and Economics from the University of Chicago.

About Imperial Capital, LLC

Imperial Capital is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer's capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital can be found at www.imperialcapital.com

About Imperial Capital (International), LLP

Imperial Capital International, founded in 2011, is an affiliate of Imperial Capital, LLC with an office in central London. Complementing Imperial Capital's existing fixed income sales and trading franchise, Imperial Capital (International), LLP expanded the Imperial Capital franchise into the EEA. The company focuses on selling the entire credit spectrum and capital structure to its European institutional clients.

For more information regarding Imperial Capital, LLC, founded in 1997, please contact:
Mark Martis
Chief Operating Officer
(310) 246-3674
mmartis@imperialcapital.com

For more information regarding Imperial Capital (International), LLP, please contact:
Brian Robertson
Managing Director
44 (0) 207 650 5401
brobertson@imperialcapital.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Imperial Capital, LLC via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

Early Warning Report23.5.2018 20:05Pressemelding

VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) announces that pursuant to a warrant exercise, it has acquired for a purchase price of C$803,571, direct ownership of 5,357,142 common shares (the "Shares") of Prospero Silver Corp. ("Prospero"), of 510 West Georgia Street, Suite 1800, Vancouver, BC V6B 0M3, at a price of C$0.15 per Share. Immediately following this transaction, Fortuna owned 10,714,284 common shares of Prospero, representing 22.74% of the issued and outstanding common shares of Prospero. Immediately prior to the transaction, Fortuna owned 5,357,142 common shares and 5,357,142 common share purchase warrants. The Shares were acquired by Fortuna for investment purposes, and depending on market and other conditions, it may from time to time in the future increase or decrease its ownership, control or direction over securities of Prospero through market transactions, private agreements, or otherwise. Fortuna has fil

GaN Systems to Showcase Innovative GaN Power Technologies and Customer Solutions at PCIM Europe 201823.5.2018 15:00Pressemelding

Record-setting GaN transistors and an array of new products, design tools, and reference designs that make it easier to develop ground-breaking power systems will be displayed OTTAWA, May 23, 2018 (GLOBE NEWSWIRE) -- GaN Systems, the global leader in GaN (gallium nitride) power semiconductors, today announced that it will be exhibiting the company's new products and design tools and presenting customer demonstrations at PCIM Europe 2018 (Power Conversion and Intelligent Motion), Booth 511 in Hall 9 (9-511) from June 5-6, 2018 in Nuremberg, Germany. At PCIM Europe, one of the leading exhibitions for power electronics and its applications, attendees to the GaN Systems booth will learn about new products, the numerous IC companies that have collaborated with GaN Systems, and a vast array of customer implementations spanning the consumer, data center, industrial, and automotive market segments. Also, GaN Systems' subject matter experts will be speaking at four sessions over the course of t

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom